Attach-2_IRB_Approval_Pitt_PRO13030229

Attach-2_IRB_Approval_Pitt_PRO13030229.pdf

Rapid Throughput Standardized Evaluation of Transmissible Risk for Substance Use Disorder in Youth (NIDA)

Attach-2_IRB_Approval_Pitt_PRO13030229

OMB: 0925-0702

Document [pdf]
Download: pdf | pdf
Attachment 2
IRB Approval: University of Pittsburgh (CEDAR)

Rapid Throughput Standardized Evaluation of
Transmissible Risk for Substance Use Disorder in Youth
(NIDA)

University of Pittsburgh
Institutional Review Board

3500 Fifth Avenue
Pittsburgh, PA 15213
(412) 383-1480
(412) 383-1508 (fax)
http://www.irb.pitt.edu

Memorandum
 

 

To:

Levent Kirisci PHD

From:

Christopher Ryan PHD, Vice Chair

Date:

4/11/2013 

IRB#:

PRO13030229

Subject: Rapid Throughput Standardized Evaluation of Transmissible Risk for SUD in Youth:
Validation Study 
The University of Pittsburgh Institutional Review Board reviewed and approved the above referenced study by the
expedited review procedure authorized under 45 CFR 46.110 and 21 CFR 56.110.  Your research study was approved
under:
45 CFR 46.110.(7) characteristics/behaviors
The risk level designation is Minimal Risk.
Approval Date:
Expiration Date:

4/11/2013
4/10/2014

For studies being conducted in UPMC facilities, no clinical activities can be undertaken by investigators until they
have received approval from the UPMC Fiscal Review Office.
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems involving risks to
subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)]. Refer to the IRB Policy and Procedure Manual
regarding the reporting requirements for unanticipated problems which include, but are not limited to, adverse events. 
If you have any questions about this process, please contact the Adverse Events Coordinator at 412-383-1480.
The protocol and consent forms, along with a brief progress report must be resubmitted at least one month prior to the
renewal date noted above as required by FWA00006790 (University of Pittsburgh), FWA00006735 (University of
Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of Pittsburgh), FWA00003567 (Magee-Womens
Health Corporation), FWA00003338 (University of Pittsburgh Medical Center Cancer Institute).
Please be advised that your research study may be audited periodically by the University of Pittsburgh Research
Conduct and Compliance Office.

https://www.osiris.pitt.edu/osiris/Doc/0/7A38I5JTHLTKVB4T4UD4IHRHF1/fromString.html[4/12/2013 12:21:54 PM]


File Typeapplication/pdf
File Titlehttps://www.osiris.pitt.edu/osiris/Doc/0/7A38I5JTHLTKVB4T4UD4IHRHF1/fromString.html
File Modified2014-03-19
File Created2013-04-12

© 2024 OMB.report | Privacy Policy